CryoPort (NASDAQ:CYRX) CEO Jerrell Shelton Sells 28,800 Shares of Stock

CryoPort, Inc. (NASDAQ:CYRX) CEO Jerrell Shelton sold 28,800 shares of the stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $14.91, for a total value of $429,408.00. Following the completion of the transaction, the chief executive officer directly owned 1,201,814 shares in the company, valued at $17,919,046.74. This trade represents a 2.34% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

CryoPort Price Performance

NASDAQ CYRX opened at $14.95 on Wednesday. CryoPort, Inc. has a 1-year low of $7.61 and a 1-year high of $16.89. The business’s 50-day simple moving average is $15.45 and its 200-day simple moving average is $11.98. The firm has a market capitalization of $757.22 million, a P/E ratio of -16.61 and a beta of 1.89.

CryoPort (NASDAQ:CYRX) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.01). CryoPort had a negative net margin of 20.05% and a negative return on equity of 7.20%. The business had revenue of $48.97 million for the quarter, compared to analyst estimates of $48.18 million. On average, equities research analysts expect that CryoPort, Inc. will post -0.83 EPS for the current fiscal year.

Institutional Trading of CryoPort

A number of hedge funds have recently made changes to their positions in CYRX. UBS Group AG raised its holdings in CryoPort by 6.8% in the fourth quarter. UBS Group AG now owns 1,421,884 shares of the company’s stock valued at $13,650,000 after acquiring an additional 90,363 shares in the last quarter. Granahan Investment Management LLC increased its position in shares of CryoPort by 475.0% in the 1st quarter. Granahan Investment Management LLC now owns 231,138 shares of the company’s stock worth $1,914,000 after purchasing an additional 190,938 shares during the last quarter. Meros Investment Management LP raised its stake in shares of CryoPort by 13.9% in the 4th quarter. Meros Investment Management LP now owns 626,427 shares of the company’s stock valued at $6,014,000 after purchasing an additional 76,687 shares in the last quarter. Renaissance Technologies LLC raised its stake in shares of CryoPort by 62.9% in the 1st quarter. Renaissance Technologies LLC now owns 368,110 shares of the company’s stock valued at $3,048,000 after purchasing an additional 142,070 shares in the last quarter. Finally, Penbrook Management LLC lifted its position in shares of CryoPort by 251.6% during the first quarter. Penbrook Management LLC now owns 185,775 shares of the company’s stock worth $1,538,000 after purchasing an additional 132,940 shares during the last quarter. Institutional investors and hedge funds own 92.90% of the company’s stock.

Analysts Set New Price Targets

CYRX has been the subject of several recent research reports. Craig Hallum increased their price objective on shares of CryoPort from $15.00 to $20.00 and gave the company a “buy” rating in a research report on Wednesday, June 3rd. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of CryoPort in a research note on Monday, August 3rd. Needham & Company LLC boosted their price objective on shares of CryoPort from $15.00 to $19.00 and gave the stock a “buy” rating in a report on Friday, August 7th. Guggenheim upped their price objective on shares of CryoPort from $12.00 to $16.00 and gave the company a “buy” rating in a research report on Friday. Finally, KeyCorp raised their target price on CryoPort from $15.00 to $17.00 and gave the company an “overweight” rating in a research note on Wednesday, May 20th. Seven analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $18.00.

CryoPort Company Profile

CryoPort, Inc (NASDAQ: CYRX) is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.

CryoPort’s product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.